ArticleFrontiers in oncology2026
Aryl hydrocarbon receptor promotes the proliferation and aggressive progression of colorectal cancer under high-fat diet via activating INPP4B/AKT/SGK3 signaling pathway.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epidemiological evidence confirms high-fat diet (HFD) as a key risk factor for colorectal cancer (CRC) progression. Aryl hydrocarbon receptor (AhR), a ligand-dependent nuclear transcription factor enriched in intestinal tissues, regulates intestinal metabolism and tumorigenesis. However, its role and mechanism in HFD-induced CRC progression remain unclear. Methods: Here, we constructed a HFD-induced obese CRC tumor-bearing mouse model and a free fatty acid (FFA)-treated CRC cell model to investigate AhR function and mechanism underlying in HFD-related CRC. Results and discussion: We found that HFD significantly promoted CRC progression, accompanying with activation of AhR with upregulated level of kynurenine (KYN) synthesis-related enzymes and increased KYN levels in tumor tissue and peripheral blood. The specific inhibition of AhR alleviated tumor growth and metastasis in tumor-bearing mouse with HFD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.